KDMN has been the subject of several other research reports. Oppenheimer assumed coverage on Kadmon in a research note on Wednesday, June 26th. They set an “outperform” rating and a $6.00 target price for the company. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, October 9th. Finally, Cantor Fitzgerald assumed coverage on Kadmon in a research note on Thursday, September 5th. They set an “overweight” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $8.95.
NYSE KDMN traded up $0.18 during trading on Monday, hitting $3.09. 589,800 shares of the company’s stock were exchanged, compared to its average volume of 830,042. The company has a current ratio of 2.99, a quick ratio of 2.98 and a debt-to-equity ratio of 0.45. The company has a market cap of $395.37 million, a PE ratio of -3.00 and a beta of 2.19. Kadmon has a fifty-two week low of $1.63 and a fifty-two week high of $3.13. The stock’s 50 day moving average price is $2.64 and its two-hundred day moving average price is $2.38.
Kadmon (NYSE:KDMN) last issued its earnings results on Monday, August 5th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.03). The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.46 million. Kadmon had a negative return on equity of 96.96% and a negative net margin of 3,974.23%. Analysts forecast that Kadmon will post -0.54 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in KDMN. Meeder Asset Management Inc. increased its stake in shares of Kadmon by 736.6% in the third quarter. Meeder Asset Management Inc. now owns 9,955 shares of the company’s stock valued at $25,000 after buying an additional 8,765 shares during the period. D. E. Shaw & Co. Inc. acquired a new position in shares of Kadmon in the second quarter valued at approximately $27,000. Parametric Portfolio Associates LLC acquired a new position in shares of Kadmon in the second quarter valued at approximately $30,000. Capital Investment Advisors LLC increased its stake in shares of Kadmon by 134.5% in the second quarter. Capital Investment Advisors LLC now owns 28,815 shares of the company’s stock valued at $59,000 after buying an additional 16,525 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Kadmon by 47.0% in the second quarter. JPMorgan Chase & Co. now owns 35,761 shares of the company’s stock valued at $70,000 after buying an additional 11,435 shares during the period. 77.02% of the stock is owned by institutional investors.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Further Reading: What is the role of the G-20?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.